Jill Lee is Director, Regulatory Policy & Intelligence at Novo Nordisk Inc., where she leads U.S. regulatory policy development and intelligence across a broad portfolio of areas, with a particular focus on cardiometabolic disease and obesity. In this role, she shapes company positions on emerging FDA policies and programs, translating complex regulatory landscapes into actionable insights for the organization. Jill has over 19 years of industry experience and began her career providing regulatory legal support for medical devices and pharmaceuticals. Jill holds a JD from Rutgers University and a BA from Mary Washington University.